Sign up to save your podcasts
Or
Share Inside NEU: The ASX pharma star with a long runway for growth
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Inside NEU: The ASX pharma star with a long runway for growth
Jump back to 2021 and Neuren Pharmaceuticals Ltd (ASX: NEU) share price consistently traded around $1.50 and occasionally breached $2. Within three years it would hit a high of $25 a share. NEU received FDA approval for a drug called Trofenetide, a drug which treats a rare syndrome called Rett Syndrome. With a drug on the shelves in the US, NEU now has the cashflows to self-fund the next leg of growth.
In this Australian Investors Podcast episode, your host Mitchell Sneddon sits down with Jon Pilcher, CEO of Neuren Pharmaceuticals (ASX: NEU) to discuss:
– The impact of trofinetide on Rett syndrome patients and families
– How Neuren partnered to distribute trofinetide in the US
– The lifecycle of drug development
– Neuren’s ability to self-fund future R&D and the opportunity with NNZ-2591
– Company culture and separating share price from business performance
If you love learning about ASX biotechs and healthcare investing, subscribe to the Australian Investors Podcast on Apple, Spotify, or YouTube!
Topics Covered
– Trofinetide’s life-changing impact on Rett syndrome patients
– The commercialisation and distribution partnership in the US
– Stages of drug development explained
– Neuren’s strategy to self-fund future growth
– The culture at Neuren Pharmaceuticals
– The potential of NNZ-2591 and timelines for progress
– Why investors should separate business performance from share price movement
Resources for This Episode
– Neuren Pharmaceuticals
– Trail to a Texas Trial
– Visit TermPlus to learn more
Rask Resources
🔗 Explore all Rask services
📋 Get Financial Planning
📈 Start investing with Rask
📜 Access Show Notes
❓ Ask a question – just select the Investors Podcast
📲 Follow us on social media:
– Instagram: @rask.invest
– TikTok: @rask.invest
DISCLAIMER
This podcast contains general financial information only. That means the information does not take into account your objectives, financial situation, or needs. You should consider if the information is appropriate for your situation before acting on it.
If you’re unsure, consult a licensed financial planner. The Rask Group is NOT a qualified tax accountant, financial adviser, or tax professional. You can access The Rask Group’s Financial Services Guide (FSG) here.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By RaskJump back to 2021 and Neuren Pharmaceuticals Ltd (ASX: NEU) share price consistently traded around $1.50 and occasionally breached $2. Within three years it would hit a high of $25 a share. NEU received FDA approval for a drug called Trofenetide, a drug which treats a rare syndrome called Rett Syndrome. With a drug on the shelves in the US, NEU now has the cashflows to self-fund the next leg of growth.
In this Australian Investors Podcast episode, your host Mitchell Sneddon sits down with Jon Pilcher, CEO of Neuren Pharmaceuticals (ASX: NEU) to discuss:
– The impact of trofinetide on Rett syndrome patients and families
– How Neuren partnered to distribute trofinetide in the US
– The lifecycle of drug development
– Neuren’s ability to self-fund future R&D and the opportunity with NNZ-2591
– Company culture and separating share price from business performance
If you love learning about ASX biotechs and healthcare investing, subscribe to the Australian Investors Podcast on Apple, Spotify, or YouTube!
Topics Covered
– Trofinetide’s life-changing impact on Rett syndrome patients
– The commercialisation and distribution partnership in the US
– Stages of drug development explained
– Neuren’s strategy to self-fund future growth
– The culture at Neuren Pharmaceuticals
– The potential of NNZ-2591 and timelines for progress
– Why investors should separate business performance from share price movement
Resources for This Episode
– Neuren Pharmaceuticals
– Trail to a Texas Trial
– Visit TermPlus to learn more
Rask Resources
🔗 Explore all Rask services
📋 Get Financial Planning
📈 Start investing with Rask
📜 Access Show Notes
❓ Ask a question – just select the Investors Podcast
📲 Follow us on social media:
– Instagram: @rask.invest
– TikTok: @rask.invest
DISCLAIMER
This podcast contains general financial information only. That means the information does not take into account your objectives, financial situation, or needs. You should consider if the information is appropriate for your situation before acting on it.
If you’re unsure, consult a licensed financial planner. The Rask Group is NOT a qualified tax accountant, financial adviser, or tax professional. You can access The Rask Group’s Financial Services Guide (FSG) here.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like Australian Investors Podcast
View all
CommSec Market Update
11 Listeners
Motley Fool Money
90 Listeners
The Money Puzzle
45 Listeners
Investopoly
18 Listeners
money money money
54 Listeners
The Rules of Investing
11 Listeners
Equity Mates Investing Podcast
64 Listeners
Australian Finance Podcast
26 Listeners
Get Started Investing
30 Listeners
Australian Business Podcast
0 Listeners
The Money Café with Alan Kohler
30 Listeners
Retire Right
30 Listeners
Australian Property Podcast
8 Listeners
Chanticleer
15 Listeners
The Fin
21 Listeners
Aussie FIRE | Financial Independence Retire Early
9 Listeners
Australian Retirement Podcast
14 Listeners
Rask Invest LIVE
0 Listeners